نتايج كموتراپي با پروتكول UKCCSG در كودكان مبتلا به لوكمي حاد ليمفوسيتيك در وب سايت ششمين همايش چالش ها در هماتولوژي کودکان ثبت شد

خلاصه فارسی

ALL تكثير كلونال و توقف هماتو پويزيز طبيعي سلولهاي ليمفوييدي مغز استخوان است كه هنوز شايعترين بدخيمي در اطفال است از سال 1960 سروايوال بيماران افزايش يافته است در اين مطالعه سروايوال 5 ساله ي بیماران مبتلابه لوکمی لیمفوبلاستیک حاد در یک مرکز هماتولوژی و اونکولوژِی را در ایران بررسی کرده در اين مطالعه سروايوال 5 ساله ي 292 بيمار كه حداكثر 15 ساله كه در سالهاي 1997 تا 2007 به بيمارستان شفای اهواز مراجعه كرده بودند وتحت درمان با پروتكول UKCCSG قرار گرفتنداز نظر سن جنس فنوتيپ ليمفوبلاستها FAB TYPE سروايوال و عود بررسي شدند متوسط سن بيماران 6.7 سال بود 184 بيمار63% مذكر بودند .بهبودی كامل در 84.9% طي اولين اينداكشن ايجاد شد.سروايوال 5 ساله 61.9% ودر موارد با ريسك استانداردبهتر بود ميزان عود بعد از اولين رميشن 23% ومرگ بيشتر در گروه با ريسك بالا بود.79 مورد 71.1% مرگها در دوره ي اينداكشن و20 مورد 6.8% بعد از ان بودند عفونت 69.4% شايعترين علت مرگ در دوره ي اينداكشن بود از نظر فنوتيپ75.3% بيماران L1و 20% L2 و 4.4% L3 بودند سروايوال كلي در پسرها و سن ا تا10 سال و تعداد گلوبول سفيد 10 تا 50 هزار بهتر بود اما از نظر آماري ارزشمند نبود

عنوان انگليسی

RESULTS OF CHEMOTHERAPY BY UKCCSG PROTOCOL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA : CLINICAL CHARACTERISTICS AND OUTCOME

خلاصه انگلیسی

Objectives: Acute lymphoblastic leukemia (ALL) represents a clonal expansion and arrest of normal lymphoid hematopoiesis. ALL remains the most common malignancy in children. The survival rate of the patients is significantly increased since the 1960s. This study was undertaken to evaluate the 5- year overall survival (OS) rates of patients with ALL in a single center in IRAN. Methodology: A total of 292 children with ALL up to 19 years old who had been treated by UKCCSG protocol at the Oncology Department in Shafa Hospital from March 1997 to October 2007 were evaluated for their age, gender, as well as FAB types, presenting features, outcomes of therapy and relapse. Results: The mean age of the patients was 6.7 years (SD= 3.8, median 6 years). In this series, 184 patients (63.01%) were male. There was a complete remission induction rate of 84.9% during first induction course of therapy. Five-year overall survival was 61.9% and it was better (p=0.006) in standard risk group. Relapse rate after first remission was 23.9% and death due to relapse was more in high risk group, but it was not significant (p=0.053). There were 74(66.6%) of total deaths in induction period and 21(18.9%) after relapse. Overall infections (71.9%) were major cause of deaths in induction period. OS was better in boys, age group between (1-10 yo) and initial white blood cells count (10,000-50,000x103/mm3) but there were not significant (p=0.38, p=0.30, p=0.20, respectively). Conclusion: Five-year overall survival was 61.9% of the children with new ALL who were undergoing chemotherapy by UKCCSG protocol. High mortality rate in induction period was mainly due to infections which decreased five-year overall survival in this study.

Document Downloads